Log in met Medi-Access

Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen

Zanubrutinib-Obinutuzumab Doubles PFS in Follicular Lymphoma

Medscape: Hematology/Oncology Headlines | Geplaatst op 17.06.2022 20:32

Over the 12-month follow-up, significantly more patients who received the combination demonstrated a durable response compared with those who received obinutuzumab alone. Medscape Medical News